Effects of statin therapy on glycemic control and insulin resistance: a systematic review and meta-analysis

Quantifying heterogeneity in a meta‐analysis

Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · see citing works

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817 · see citing works

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156 · see citing works

General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study

D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491 · see citing works

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp

Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · see citing works

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · see citing works

2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetes—2020</i>

American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187 · see citing works

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity

Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456 · see citing works

Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials

Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · see citing works

Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program

Lévy, J., Matthews, D. R., & Hermans, M. P. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2191 · Cited by 1,997 · see citing works

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

Schächter, M. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,216 · see citing works

Adiponectin and protection against type 2 diabetes mellitus

Spranger, J., Kroke, A., Möhlig, M., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12255-6 · Cited by 1,120 · see citing works

Evidence for physiotherapy practice: A survey of the Physiotherapy Evidence Database (PEDro)

Moseley, A. M., Herbert, R. D., Sherrington, C., & Maher, C. G. (2002) · Australian Journal of Physiotherapy · doi:10.1016/s0004-9514(14)60281-6 · Cited by 911 · see citing works

Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes

Klein, R. (1995) · Diabetes Care · doi:10.2337/diacare.18.2.258 · Cited by 849 · see citing works

Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844 · see citing works

The safety of statins in clinical practice

Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833 · see citing works

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816 · see citing works

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions

Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 574 · see citing works

Hepatic and peripheral insulin resistance: A common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus

DeFronzo, R. A., Simonson, D. C., & Ferrannini, E. (1982) · Diabetologia · doi:10.1007/bf00253736 · Cited by 539 · see citing works

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials

Mills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338 · see citing works

Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin

Waters, D. D., Ho, J. E., DeMicco, D. A., Breazna, A., Arsenault, B. J., Wun, C.-C., Kastelein, J. J., Colhoun, H., & Barter, P. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.047 · Cited by 333 · see citing works

Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort

Cederberg, H., Stančáková, A., Yaluri, N., Modi, S. R., Kuusisto, J., & Laakso, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3528-5 · Cited by 316 · see citing works

Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose

Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2713 · Cited by 313 · see citing works

Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus

Navarese, E. P., Buffon, A., Andreotti, F., Koziński, M., Welton, N. J., Fabiszak, T., Caputo, S., Grześk, G., Kubica, A., Świątkiewicz, I., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.037 · Cited by 309 · see citing works

Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control

Nakata, M., Nagasaka, S., Kusaka, I., Matsuoka, H., Ishibashi, S., & Yada, T. (2006) · Diabetologia · doi:10.1007/s00125-006-0269-5 · Cited by 295 · see citing works

Glycemic Variability

Monnier, L., & Colette, C. (2008) · Diabetes Care · doi:10.2337/dc08-s241 · Cited by 267 · see citing works

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

Freed, M. I., Ratner, R. E., Marcovina, S. M., Kreider, M. S., Biswas, N., Cohen, B. R., & Brunzell, J. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02659-0 · Cited by 238 · see citing works

Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca 2+ signalling and insulin secretion due to blockade of L‐type Ca 2+ channels in rat islet β‐cells

Yada, T., Nakata, M., Shiraishi, T., & Kakei, M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702397 · Cited by 229 · see citing works

Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients

Koh, K. K., Quon, M. J., Han, S. H., Lee, Y., Kim, S. J., & Shin, E. K. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.053 · Cited by 229 · see citing works

Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome

Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219 · see citing works

Statin treatment and new-onset diabetes: A review of proposed mechanisms

Brault, M., Ray, J., Sandoval, Y.-H. G., Mantzoros, C. S., & Daskalopoulou, S. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.02.014 · Cited by 218 · see citing works

Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes

Sarafidis, P. A., Lasaridis, A. N., Nilsson, P. M., Pikilidou, M. I., STAFILAS, P., Kanaki, A., Kazakos, K., Yovos, J. G., & Bakris, G. L. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002201 · Cited by 197 · see citing works

Effect of NCB-02, Atorvastatin and Placebo on Endothelial Function, Oxidative Stress and Inflammatory Markers in Patients with Type 2 Diabetes Mellitus

Usharani, P., Mateen, A., Naidu, M. U. R., Raju, Y. S. N., & Chandra, N. (2008) · Drugs in R&D · doi:10.2165/00126839-200809040-00004 · Cited by 195 · see citing works

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy

Lam, K. S. L., Cheng, I. K. P., Janus, E. D., & Pang, R. W. C. (1995) · Diabetologia · doi:10.1007/bf00400731 · Cited by 190 · see citing works

Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis

Baker, W. L., Talati, R., White, C. M., & Coleman, C. I. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.008 · Cited by 186 · see citing works

Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis.

Goldstein, J. L., & Brown, M. S. (1987) · Circulation · doi:10.1161/01.cir.76.3.504 · Cited by 179 · see citing works

Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity

Chan, D. C., Watts, G. F., Barrett, P. H. R., Beilin, L. J., & Mori, T. A. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.6.877 · Cited by 150 · see citing works

Different Time Trends of Caloric and Fat Intake Between Statin Users and Nonusers Among US Adults

Sugiyama, T., Tsugawa, Y., Tseng, C., Kobayashi, Y., & Shapiro, M. F. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1927 · Cited by 144 · see citing works

Statin use and risk of developing diabetes: results from the Diabetes Prevention Program

Crandall, J. P., Mather, K., Rajpathak, S. N., Goldberg, R. B., Watson, K., Foo, S., Ratner, R., Barrett-Connor, E., & Temprosa, M. (2017) · BMJ Open Diabetes Research &amp; Care · doi:10.1136/bmjdrc-2017-000438 · Cited by 137 · see citing works

Trends in lipid-modifying agent use in 83 countries

Blais, J. E., Wei, Y., Yap, K. K. W., Alwafi, H. H., Ma, T., Brauer, R., Lau, W. C. Y., Man, K. K. C., Siu, C. W., Tan, K. C. B., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.016 · Cited by 131 · see citing works

The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia

The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1335 · Cited by 128 · see citing works

Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes

Vallejo‐Vaz, A. J., Seshasai, S. R. K., Kurogi, K., Michishita, I., Nozue, T., Sugiyama, S., Tsimikas, S., Yoshida, H., & Ray, K. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.001 · Cited by 123 · see citing works

Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients

Koh, K. K., Quon, M. J., Han, S. H., Lee, Y., Kim, S. J., Park, J. B., & Shin, E. K. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.021 · Cited by 119 · see citing works

Are statins diabetogenic?

Sampson, U. K. A., Linton, M. F., & Fazio, S. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283470359 · Cited by 116 · see citing works

Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients

Koh, K. K., Quon, M. J., Han, S. H., Lee, Y., Ahn, J. Y., Kim, S. J., Koh, Y., & Shin, E. K. (2008) · Diabetes Care · doi:10.2337/dc07-2199 · Cited by 114 · see citing works

A 52-Week, Randomized, Open-Label, Parallel-Group Comparison of the Tolerability and Effects of Pitavastatin and Atorvastatin on High-Density Lipoprotein Cholesterol Levels and Glucose Metabolism in Japanese Patients with Elevated Levels of Low-Density Lipoprotein Cholesterol and Glucose Intolerance

Sasaki, J. D., Ikeda, Y., Kuribayashi, T., Kajiwara, K., Biro, S., Yamamoto, K., Ageta, M., Kobori, S., Saikawa, T., Otonari, T., et al. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.017 · Cited by 109 · see citing works

Effect of Cerivastatin on Urinary Albumin Excretion and Plasma Endothelin-1 Concentrations in Type 2 Diabetes Patients with Microalbuminuria and Dyslipidemia

Nakamura, T., Ushiyama, C., Hirokawa, K., et al. (2001) · American Journal of Nephrology · doi:10.1159/000046648 · Cited by 88 · see citing works

Effects of Atorvastatin and Pravastatin on Signal Transduction Related to Glucose Uptake in 3T3L1 Adipocytes

Takaguri, A., Satoh, K., Itagaki, M., Tokumitsu, Y., & Ichihara, K. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0072403 · Cited by 87 · see citing works

Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes—the CORALL study

Şimşek, S., Schalkwijk, C., & Wolffenbuttel, B. H. R. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03553.x · Cited by 83 · see citing works

Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease

Sugiyama, S., Fukushima, H., Kugiyama, K., Maruyoshi, H., Kojima, S., Funahashi, T., Sakamoto, T., Horibata, Y., Watanabe, K., Koga, H., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.023 · Cited by 81 · see citing works

Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes

Pontrelli, L., Parris, W. E., Adeli, K., & Cheung, R. C. (2002) · Metabolism · doi:10.1053/meta.2002.30510 · Cited by 80 · see citing works

Effect of Atorvastatin (10 mg/day) on Glucose Metabolism in Patients With the Metabolic Syndrome

Huptas, S., Geiss, H. C., Otto, C., & Parhofer, K. G. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.055 · Cited by 80 · see citing works

Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance

Moutzouri, E., Liberopoulos, E. N., Mikhailidis, D. P., Kostapanos, M. S., Kei, A. A., Milionis, H. J., & Elisaf, M. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02779.x · Cited by 76 · see citing works

Cerivastatin Improves Insulin Sensitivity and Insulin Secretion in Early-State Obese Type 2 Diabetes

Paniagua, J. A., López‐Miranda, J., Escribano, A., Berral, F. J., Marı́n, C., Bravo, D., Paz-Rojas, E., Gomez, P. J., Barcos, M., Moreno, J. A., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2596 · Cited by 74 · see citing works

Effects of Simvastatin and Metformin on Inflammation and Insulin Resistance in Individuals with Mild Metabolic Syndrome

Bulc??o, C., Ribeiro‐Filho, F. F., Sañudo, A., & Ferreira, S. G. R. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707030-00007 · Cited by 71 · see citing works

Effect of Simvastatin and Fenofibrate on Cytokine Release and Systemic Inflammation in Type 2 Diabetes Mellitus With Mixed Dyslipidemia

Krysiak, R. G., Gdula‐Dymek, A., & Okopień, B. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.023 · Cited by 70 · see citing works

Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes

Krysiak, R. G., Gdula‐Dymek, A., Bachowski, R., & Okopień, B. (2010) · Diabetes Care · doi:10.2337/dc10-0272 · Cited by 69 · see citing works

Effects of Maximal Atorvastatin and Rosuvastatin Treatment on Markers of Glucose Homeostasis and Inflammation

Thongtang, N., Ai, M., Otokozawa, S., Himbergen, T. V., Asztalos, B. F., Nakajima, K., Stein, E. A., Jones, P. H., & Schaefer, E. J. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.09.031 · Cited by 68 · see citing works

Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes

Jinnouchi, Y., Yamagishi, S., Takeuchi, M., Ishida, S., Jinnouchi, Y., Jinnouchi, J., & Imaizumi, T. (2006) · Clinical and Experimental Medicine · doi:10.1007/s10238-006-0115-6 · Cited by 67 · see citing works

Time‐ and Dose‐Dependent Association of Statin Use With Risk of Clinically Relevant New‐Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study

Ko, M. J., Jo, A. J., Kim, Y. J., Kang, S. H., Cho, S., Jo, S., Park, C., Yun, S., Lee, W. J., & Park, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011320 · Cited by 63 · see citing works

Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism

Kain, V., Kapadia, B. B., Misra, P., & Saxena, U. (2015) · Scientific Reports · doi:10.1038/srep13823 · Cited by 57 · see citing works

Simvastatin in non-insulin-dependent diabetes mellitus: Effect on serum lipids, lipoproteins and haemostatic measures

Farrer, M., Winocour, P. H., Evans, K., Neil, H. A. W., Laker, M. F., Kesteven, P. J., & Alberti, K. G. M. M. (1994) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(94)90018-3 · Cited by 53 · see citing works

Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients

Koh, K. K., Quon, M. J., Sakuma, I., Han, S. H., Choi, H., Lee, K., & Shin, E. K. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.028 · Cited by 53 · see citing works

Effects of High-Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Nonobese Type 2 Diabetic Patients

Szendroedi, J., Anderwald, C. H., Krššák, M., Bayerle‐Eder, M., Esterbauer, H., Pfeiler, G., Brehm, A., Nowotny, P., Hofer, A., Waldhäusl, W. K., et al. (2008) · Diabetes Care · doi:10.2337/dc08-1123 · Cited by 53 · see citing works

Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients

Parhofer, K. G., Laubach, E., & Barrett, P. H. R. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300011-jlr200 · Cited by 53 · see citing works

Simvastatin (40 mg/day), Adiponectin Levels, and Insulin Sensitivity in Subjects With the Metabolic Syndrome

Devaraj, S., Siegel, D., & Jialal, I. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.028 · Cited by 49 · see citing works

Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.

Schneider, J. G., von Eynatten, M., Parhofer, K., Volkmer, J., Schiekofer, S., Hamann, A., Nawroth, P., & Dugi, K. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.04.003 · Cited by 48 · see citing works

Atorvastatin improves metabolic control and endothelial function in Type 2 diabetic patients: A placebo-controlled study

Nora, E. D., Passaro, A., Zamboni, P., Calzoni, F., Fellin, R., & Solini, A. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03345126 · Cited by 47 · see citing works

Atorvastatin 10 mg plus ezetimibe 10 mg compared with atorvastatin 20 mg: Impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease

Uemura, Y., Watarai, M., Ishii, H., Koyasu, M., Takemoto, K., Yoshikawa, D., Shibata, R., Matsubara, T., & Murohara, T. (2011) · Journal of Cardiology · doi:10.1016/j.jjcc.2011.09.001 · Cited by 46 · see citing works

Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia

Park, J., Kim, Y.-J., Kim, Y.-J., et al. (2010) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2010.25.1.27 · Cited by 46 · see citing works

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)

Livingstone, S. J., Looker, H. C., Akbar, T., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Fuller, J., & Colhoun, H. M. (2015) · Diabetologia · doi:10.1007/s00125-015-3802-6 · Cited by 46 · see citing works

Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study

Anagnostis, P. G., Selalmatzidou, D., Pοlyzos, S. A., Panagiotou, A., Slavakis, A., Panagiotidou, A., Athyros, V. G., Karagiannis, A. I., Mikhailidis, D. P., & Kita, M. D. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02655.x · Cited by 44 · see citing works

Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism

Her, A., Kim, J., Kang, S., Choi, D., Jang, Y., Chung, N., Manabe, I., & Lee, S. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409357922 · Cited by 44 · see citing works

Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin

Sviridov, D., Hoang, A., Ooi, E. M. M., Watts, G. F., Barrett, P. H. R., & Nestel, P. J. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.007 · Cited by 44 · see citing works

Risk of New-Onset Diabetes Mellitus Versus Reduction in Cardiovascular Events With Statin Therapy

Wang, K.-L., Liu, C., Chao, T., Chen, S., Wu, C., Huang, C.-M., Chang, C. C., Wang, K.-F., Chen, T., Lin, S., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.10.043 · Cited by 43 · see citing works

Effectiveness of diabetes mellitus screening recommendations

Dallo, F. J., & Weller, S. C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1733839100 · Cited by 41 · see citing works

Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia

Nakagomi, A., Shibui, T., Kohashi, K., Kosugi, M., Kusama, Y., Atarashi, H., & Shimizu, W. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.29520 · Cited by 40 · see citing works

Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome

Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., Nestel, P. J., & Watts, G. F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.004 · Cited by 39 · see citing works

Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes

Chu, C. H., Lee, J. K., Lam, H. ‐., Lu, C. C., Sun, C.-C., Wang, M.-S., Chuang, M.-J., & Wei, M. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345565 · Cited by 38 · see citing works

Pitavastatin and Atorvastatin Double-Blind Randomized ComPArative Study among HiGh-Risk Patients, Including ThOse with Type 2 Diabetes Mellitus, in Taiwan (PAPAGO-T Study)

Liu, P., Lin, L., Lin, H., Hsia, C., Hung, Y.-R., Yeh, H., Wu, T.-C., Chen, J., Chien, K., & Chen, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076298 · Cited by 38 · see citing works

Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality

Lim, S. K., Sakuma, I., Quon, M. J., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.037 · Cited by 36 · see citing works

Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia

Pareek, A. K., Chandurkar, N. B., Thulaseedharan, N. K., Legha, R., Agarwal, M., Mathur, S., Salkar, H. R., Pednekar, S., Pai, V., Sriram, U., et al. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1087989 · Cited by 36 · see citing works

Intense Cholesterol Lowering Therapy with a HMG-CoA Reductase Inhibitor does not Improve Nitric Oxide Dependent Endothelial Function in Type-2-Diabetes

Balletshofer, B. M., Goebbel, S., Rittig, K., et al. (2005) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2005-865642 · Cited by 34 · see citing works

Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia

Werida, R. H., Khairat, I., & Khedr, N. F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111179 · Cited by 34 · see citing works

Prevalence of metabolic syndrome in Galicia (NW Spain) on four alternative definitions and association with insulin resistance

Tomé, M. A., Botana, M., Cadarso-Suárez, C., Iraeta, A. R., Fernández-Mariño, A., Mato, J. A. M., Solache, I., & Pérez-Fernández, R. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346497 · Cited by 32 · see citing works

Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation

Sun, B., Zhong, Z., Wang, F., Xu, J., Xu, F., Kong, W., Ling, Z., Shu, N., Li, Y., Wu, T., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.021 · Cited by 32 · see citing works

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial

Braun, L. R., Feldpausch, M. N., Czerwonka, N., Weiss, J. J., Branch, K. L., Lee, H., Martínez-Salazar, E. L., Torriani, M., Sponseller, C. A., Grinspoon, S. K., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01446 · Cited by 32 · see citing works

Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe

Kater, A. L. D. A., Batista, M. C., & Ferreira, S. R. G. (2010) · Metabolism · doi:10.1016/j.metabol.2010.02.011 · Cited by 31 · see citing works

IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes

Bonifacio, A., Sanvee, G. M., Brecht, K., Kratschmar, D. V., Odermatt, A., Bouitbir, J., & Krähenbühl, S. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1871-z · Cited by 31 · see citing works

EFFECTS OF ATORVASTATIN AND PRAVASTATIN ON GLUCOSE TOLERANCE, ADIPOKINE LEVELS AND INFLAMMATORY MARKERS IN HYPERCHOLESTEROLAEMIC PATIENTS

Ando, H., Sugimoto, K., Yanagihara, H., Tsuruoka, S., Saito, T., Takamura, T., Kaneko, S., & Fujimura, A. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04945.x · Cited by 30 · see citing works

High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study

May, H. T., Knowlton, K. U., Anderson, J. L., LAPPE, D. L., Bair, T. L., & Muhlestein, J. B. (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab024 · Cited by 30 · see citing works

Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia

Kostapanos, M. S., Milionis, H. J., Lagos, K. G., Rizos, C. V., Tselepis, A. D., & Elisaf, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.007 · Cited by 26 · see citing works

A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia

Tanaka, A., Yamada, N., Saitō, Y., Kawakami, M., Ohashi, Y., & Akanuma, Y. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00589-7 · Cited by 25 · see citing works

Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled factorial trial

Neil, H. A. W., Ceglarek, U., Thiery, J., Paul, S. K., Farmer, A. A., & Holman, R. R. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.013 · Cited by 24 · see citing works

Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients

Koh, K. K., Oh, P. C., Sakuma, I., Lee, Y., Han, S. H., & Shin, E. K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.051 · Cited by 22 · see citing works

Effects of statin therapy and exercise on postprandial triglycerides in overweight individuals with hypercholesterolaemia

Mora‐Rodríguez, R., ORTEGA, J. F., Morales‐Palomo, F., Ramírez-Jiménez, M., & Moreno‐Cabañas, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14217 · Cited by 22 · see citing works

No Effect of Simvastatin Treatment on Insulin Sensitivity in Patients with Primary Hypercholesterolemia

Altunbaş, H., Balcı, M. K., & Karayalçın, Ü. (2003) · Endocrine Research · doi:10.1081/erc-120025034 · Cited by 21 · see citing works

Short‐Term Effect of Atorvastatin on Endothelial Function in Healthy Offspring of Parents with Type 2 Diabetes Mellitus

Kadirvelu, A., Choy, A. M., Mustafa, M. R., & Lang, C. C. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00064.x · Cited by 20 · see citing works

The Effect of Rosuvastatin on Insulin Sensitivity and Pancreatic Beta-Cell Function in Nondiabetic Renal Transplant Recipients

Sharif, A., Ravindran, V. K., Moore, R., Dunseath, G. J., Luzio, S. D., Owens, D. R., & Baboolal, K. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02644.x · Cited by 19 · see citing works

The effects of improved metabolic risk factors on bone turnover markers after 12 weeks of simvastatin treatment with or without exercise

Jiang, J., Boyle, L. J., Mikus, C. R., Oberlin, D. J., Fletcher, J. A., Thyfault, J. P., & Hinton, P. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.07.011 · Cited by 19 · see citing works

The effects of pitavastatin on glucose metabolism in patients with type 2 diabetes with hypercholesterolemia

Daido, H., Horikawa, Y., & Takeda, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.048 · Cited by 18 · see citing works

Colesevelam Plus Rosuvastatin 5 mg/Day Versus Rosuvastatin 10 mg/Day Alone on Markers of Insulin Resistance in Patients with Hypercholesterolemia and Impaired Fasting Glucose

Florentin, M., Liberopoulos, E. N., Rizos, C. V., Kei, A. A., Liamis, G. L., Kostapanos, M. S., & Elisaf, M. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0103 · Cited by 18 · see citing works

The Statins in Prevention of Coronary Heart Diseases in Type 2 Diabetics

Heljić, B., Velija-Ašimi, Z., & Kulić, M. (2009) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2009.2860 · Cited by 18 · see citing works

Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome

Leo, V. D. (2000) · Human Reproduction · doi:10.1093/humrep/15.11.2302 · Cited by 17 · see citing works

Glucose Metabolism After Kidney Transplantation: Insulin Release and Sensitivity With Tacrolimus- Versus Belatacept-Based Immunosuppression

Müller, M. M., Schwaiger, E., Kurnikowski, A., Haidinger, M., Ristl, R., Tura, A., Pacini, G., Werzowa, J. M., & Hecking, M. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.07.016 · Cited by 16 · see citing works

Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia

Melenovský, V., Malík, J., Wichterle, D., Šimek, J., Písaříková, A., Škrha, J., Poledne, R., Stávek, P., & Češka, R. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124833 · Cited by 16 · see citing works

Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study

Sasaki, J., Otonari, T., Uchida, Y., Ikeda, Y., Biro, S., & Kono, S. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13532 · Cited by 15 · see citing works

Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients

Teixeira, A. A. D. S., Buffani, A., Tavares, A., Ribeiro, A. B., Zanella, M. T., Kohlmann, O., & Batista, M. C. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2010.87 · Cited by 14 · see citing works

Effect of Atorvastatin on Pancreatic Beta-Cell Function and Insulin Resistance in Type 2 Diabetes Mellitus Patients: A Randomized Pilot Study

Goyal, A., Singh, S., Tandon, N., et al. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.01.006 · Cited by 14 · see citing works

Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus

Kim, J., Lee, M.-R., Shin, J.-A., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.045 · Cited by 14 · see citing works

Effects of Ezetimibe/Simvastatin 10/20 mg vs. Atorvastatin 20 mg on Apolipoprotein B/Apolipoprotein A1 in Korean Patients with Type 2 Diabetes Mellitus: Results of a Randomized Controlled Trial

Lee, J., Kang, H., Kim, H.-S., Sohn, D., Oh, B., & Park, Y.-B. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0031-6 · Cited by 13 · see citing works

Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study

Cho, K. I., Kim, B. H., Park, Y. H., Ahn, J.-C., Kim, S., Chung, W., Kim, W., Sohn, I. S., Shin, J., Kim, Y. J., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.05.007 · Cited by 13 · see citing works

Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study

Lee, H., Han, K., Chung, W., Her, S., Park, T., Rha, S., Choi, S., Jung, K.-T., Park, J., Kim, P.-J., et al. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.013 · Cited by 12 · see citing works

Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia

Lee, W., Lee, W.-L., Tang, Y., Liang, K., Chien, Y.-H., Tsou, S. S., & Sheu, W. H. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.12.013 · Cited by 11 · see citing works

Effects of statins and exercise on postprandial lipoproteins in metabolic syndrome vs metabolically healthy individuals

Álvarez-Jiménez, L., Moreno‐Cabañas, A., Ramírez-Jiménez, M., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14447 · Cited by 11 · see citing works

Efficacy and safety of fixed‐dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double‐blind, controlled, phase 3 trial

Bae, J. C., Min, K. W., Kim, Y. H., Kim, K., Hong, E., Park, C., Han, S. Y., & Cha, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13491 · Cited by 10 · see citing works

Effect of Atorvastatin on blood ketone levels and glycemic control in patients with type 2 diabetes mellitus: A single arm pilot study

Baul, P. B., Deepak, A. D., Kakkar, M., & Modi, S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.020 · Cited by 10 · see citing works

Comparison of Efficacy of Pitavastatin and Colestimide in Japanese Patients with Diabetes Mellitus Complicated by Hyperlipidemia and Metabolic Syndrome

Kato, T., Inagaki, K., Sawai, Y., et al. (2011) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0031-1273770 · Cited by 8 · see citing works

Response to Letter to the Editor Allard et al: “Exercise Training Adaptations in Metabolic Syndrome Individuals on Chronic Statin Treatment”

Morales‐Palomo, F., Ramírez-Jiménez, M., ORTEGA, J. F., Moreno‐Cabañas, A., Álvarez-Jiménez, L., & Mora‐Rodríguez, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa420 · Cited by 3 · see citing works

Clinical practice guidelines for the care of girls and women with Turner syndrome.

Gravholt, C. H., Andersen, N. H., Christin-Maitre, S., Davis, S. M., Duijnhouwer, A., Gawlik, A., Maciel-Guerra, A. T., Gutmark-Little, I., Fleischer, K., Hong, D., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae050 · Cited by 224 · see citing works

Insulin Resistance in Young Obese Subjects and Its Relation to Smoking (A Pilot Study)

Juneja, A., Dwivedi, S., Srivastava, D., et al. (2016) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-016-0579-4 · Cited by 15 · see citing works

Correlation nitric oxide level and homeostatic model assessment insulin resistance in obese adolescent

Julinar, J., Rini, E. A., Bachtiar, H., et al. (2013) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2013-s1-p84 · Cited by 2 · see citing works

Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes

Birkenfeld, A. L., & Shulman, G. I. (2013) · Hepatology · doi:10.1002/hep.26672 · Cited by 740 · see citing works

Can viscous fiber lower glycemic markers in type 2 diabetes?

Meisenheimer (2021) · The Journal of Family Practice · doi:10.12788/jfp.0141 · Cited by 1 · see citing works

Adipocytokine levels in nonalcoholic fatty liver disease #

van der Poorten, D., Milner, K., Chisholm, D. J., & George, J. (2009) · Hepatology · doi:10.1002/hep.23088